Table 1. Main characteristics of all the studies included in the meta-analysis.
| First author | Year | Study region | Sample | NOS | Age (years) | N.of M/F | Primary antibody | Treatment | Follow-up(months) |
|---|---|---|---|---|---|---|---|---|---|
| Gundewar[23] | 2015 | Sweden | Tissue | 7 | 66(48–84) | 43/45 | mouse mAb | surgery | about 10 years |
| Hidalgo[24] | 2015 | Spain | Tissue | 6 | NR | NR | mouse mAb | chemotherapy | >30 |
| Infante[25] | 2007 | USA | Tissue | 8 | 67 | NR | mouse mAb | surgery | >48 |
| Mantoni[26] | 2008 | UK | Tissue | 7 | NR | 27/22 | mouse mAb | CRT | >70 |
| Mao[27] | 2014 | China | Tissue | 6 | <60:72 | 86/64 | mAb | surgery | >36 |
| ≥60:78 | |||||||||
| Miyoshi[28] | 2010 | Japan | Tissue | 8 | 66(36–86) | 66/38 | - | surgery | median20(1–101) |
| Ormanns[29] | 2015 | Germany | Tissue | 6 | 62 | NR | mouse mAb | chemotherapy | NR |
| Prenzel[30] | 2006 | Germany | Tissue | 7 | 59.4(33–81) | 24/15 | - | surgery | median9.5 |
| Sinn[31] | 2014 | Germany | Tissue | 7 | 62(36–81) | 65/95 | mouse mAb | surgery | >100 |
| Von Hoff[32] | 2011 | USA | Tissue | 6 | 61.7(28–86) | 32/35 | mAb and pAb | chemotherapy | >20 |
N. Of P.: the number of patients; mAb: monoclonal antibody; pAb: polyclonal antibody; NR: Not reported; CRT: chemoradiotherapy; Mao and Von Hoff didn’t explain what kind of Ab, so we consider them as other Abs; In the column of age, for example, 66(48–84) means mean (ranges).